Extended Data Fig. 6: EVT0185 decreases RER,14C-glucose incorporation into lipid and tumor burden in mouse liver.
From: ACLY inhibition promotes tumour immunity and suppresses liver cancer
a, Effect of a single dose of EVT0185 on RER (Respiratory Exchange Ratio) in C57BL-6 mice. Each line graph represents the mean ± SEM, P values by unpaired two-tailed t-test, EVT0185 (n = 8) vs. vehicle-treated (n = 9) mice. b, 14C-glucose incorporation into fatty acids and cholesterol in the liver isolated from C57BL-6 mice treated with EVT0185 for 7 days. Each bar represents the mean ± SEM, Vehicle (n = 10), EVT0185-10 (n = 6), 30 (n = 7), and 60 (n = 6) mg/kg-treated mice, one-way ANOVA followed by Tukey’s multiple comparisons. c, Experimental Scheme of WD-DEN HCC model. d, Serum-AFP levels before starting treatment, and e, tumor surface area after treatments. Data as mean ± SEM, Vehicle (n = 12), EVT0185-30 and 100 mg/kg (n = 12) and Bempedoic acid (n = 4)-treated mice; one-way ANOVA with Fisher’s LSD. (f-g) f, Representative images showing tumor lipid droplets (Scale bars are 600 µm) and bar diagram showing percentage area of a lipid and g, average lipid droplet size in tumor, each bar represents the mean ± SEM, n = 6 mice/group, P values by unpaired two-tailed t-test. h, WD-fed mice with elevations in AFP at 18 months before starting treatment. Each bar represents the mean ± SEM, n = 5 mice/group, P values by unpaired two-tailed t-test. i, Sum of tumor diameter per mouse liver. Each bar represents the mean ± SEM, Treatment groups (n = 12) vs. vehicle-treated mice (n = 10), P values by one-way ANOVA followed by Fisher’s LSD multiple comparisons: P = 1.99 × 10−5 (EVT0185-100 vs. vehicle), P = 1.14 × 10−5 (EVT0185+Soraf vs. vehicle) and P = 4.57 × 10−6 (EVT0185+Lenva vs. vehicle). j, Tumor surface area. Each bar represents the mean ± SEM, Isotype control (n = 11), PDL1 + VEGFR2 Ab (n = 10), and EVT0185 + PDL1 + VEGFR2Ab (n = 11) injected mice, P values by one-way ANOVA followed by Fisher’s LSD multiple comparisons.
